Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion

被引：36

作者：

Carmi, C. ^{[1
]}

Lodola, A. ^{[1
]}

Rivara, S. ^{[1
]}

Vacondio, F. ^{[1
]}

Cavazzoni, A. ^{[2
]}

Alfieri, R. R. ^{[2
]}

Ardizzoni, A. ^{[3
]}

Petronini, P. G. ^{[2
]}

Mor, M. ^{[1
]}

机构：

[1] Univ Parma, Dipartimento Farmaceut, I-43124 Parma, Italy

[2] Univ Parma, Dipartimento Med Sperimentale, I-43125 Parma, Italy

[3] Azienda Osped Univ Parma, I-43126 Parma, Italy

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2011年 / 11卷 / 12期

关键词：

Antitumor; covalent inhibition; cysteine-trap; EGFR; erbB receptors; irreversible inhibitors; NSCLC; TYROSINE KINASE INHIBITORS; CELL LUNG-CANCER; PHASE-I; ACQUIRED-RESISTANCE; COVALENT MODIFIERS; EGF RECEPTOR; MECHANISMS; MUTATIONS; AFFINITY; DESIGN;

D O I：

10.2174/138955711797247725

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Covalent EGFR irreversible inhibitors showed promising potential for the treatment of gefitinib-resistant tumors and for imaging purposes. They contain a cysteine-reactive portion forming a covalent bond with the protein. Irreversible kinase inhibitors have been advanced to clinical studies, mostly characterized by an acrylamide or butynamide warhead. However, the clinical usefulness of these compounds has been hampered by resistances, toxicity and pharmacokinetic problems. Investigation on the structure-activity and structure-reactivity relationships may provide useful information for compounds with improved selectivity and pharmacokinetic properties. This review focuses on the exploration of the cysteine-trap portions able to irreversibly inhibit EGFR and other erbB receptors.

引用

页码：1019 / 1030

页数：12

共 64 条

[1] Multitarget-directed drug design strategy: A novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects [J].

Antonello, Alessandra ;

Tarozzi, Andrea ;

Morroni, Fabiana ;

Cavalli, Andrea ;

Rosini, Michela ;

Hrelia, Patrizia ;

Bolognesi, Maria Laura ;

Melchiorre, Carlo .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (23) :6642-6645

[2] Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase [J].

Ban, Hyun Seung ;

Usui, Taikou ;

Nabeyama, Wataru ;

Morita, Hidetoshi ;

Fukuzawa, Kaori ;

Nakamura, Hiroyuki .

ORGANIC & BIOMOLECULAR CHEMISTRY, 2009, 7 (21) :4415-4427

[3] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].

Barker, AJ ;

Gibson, KH ;

Grundy, W ;

Godfrey, AA ;

Barlow, JJ ;

Healy, MP ;

Woodburn, JR ;

Ashton, SE ;

Curry, BJ ;

Scarlett, L ;

Henthorn, L ;

Richards, L .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914

[4] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].

Baselga, J ;

Arteaga, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459

[5] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[6] Structure-guided development of affinity probes for tyrosine kinases using chemical genetics [J].

Blair, Jimmy A. ;

Rauh, Daniel ;

Kung, Charles ;

Yun, Cai-Hong ;

Fan, Qi-Wen ;

Rode, Haridas ;

Zhang, Chao ;

Eck, Michael J. ;

Weiss, William A. ;

Shokat, Kevan M. .

NATURE CHEMICAL BIOLOGY, 2007, 3 (04) :229-238

[7] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

[8]

Camp ER, 2005, CLIN CANCER RES, V11, P397

[9] Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion [J].

Carmi, Caterina ;

Cavazzoni, Andrea ;

Vezzosi, Stefano ;

Bordi, Fabrizio ;

Vacondio, Federica ;

Silva, Claudia ;

Rivara, Silvia ;

Lodola, Alessio ;

Alfieri, Roberta R. ;

La Monica, Silvia ;

Galetti, Maricla ;

Ardizzoni, Andrea ;

Petronini, Pier Giorgio ;

Mor, Marco .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (05) :2038-2050

[10] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].

Carter, TA ;

Wodicka, LM ;

Shah, NP ;

Velasco, AM ;

Fabian, MA ;

Treiber, DK ;

Milanov, ZV ;

Atteridge, CE ;

Biggs, WH ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Mehta, SA ;

Patel, HK ;

Pao, W ;

Sawyers, CL ;

Varmus, H ;

Zarrinkar, PP ;

Lockhart, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016

← 1 2 3 4 5 6 7 →